-
公开(公告)号：US20210105980A1
公开(公告)日：2021-04-15
申请号：US17050199
申请日：2019-04-25
摘要： A method of tracking an animal (4) in a population of animals (4) comprises: applying a visual identifier (41) to the animal (4); associating reference identifier data of the visual identifier (41) to animal data of the animal (4); capturing a digital image of the visual identifier (41) applied to the animal (4); recognizing the visual identifier (41) by digitally processing the captured digital image; and identifying the animal (4) upon recognition of the visual identifier (41).
-
公开(公告)号：US20210003559A1
公开(公告)日：2021-01-07
申请号：US16912391
申请日：2020-06-25
发明人： Cristina Bertinetti-Lapatki , Lauriane Cabon , Adrian B. Roth , Annie Moisan , Nikolche Gjorevski , Jordan S. Kerns , Geraldine A. Hamilton , Catherine Karalis , Heather Grant , Riccardo Barrile , Debora Barreiros Petropolis , Chaitra Belgur
IPC分类号： G01N33/50
摘要： Disclosed herein is a method for assessing a compound interacting with a target on polarized epithelial cells. The method comprising the steps of providing an organ chip comprising a main channel and polarized epithelial cells, wherein the main channel is divided into an apical channel and a basal channel separated by the polarized epithelial cells, wherein the apical side of the polarized epithelial cells is directed towards the apical channel and the basolateral side of the polarized epithelial cells is directed towards the basal channel. Determining the localization and optionally the expression level of the target on the polarized epithelial cells. Administering the compound and optionally immune cells, preferably peripheral blood mononuclear cells (PBMC) to the basal channel, when the target is localized on the basolateral side of the epithelial cells or administering the compound and optionally immune cells, preferably peripheral blood mononuclear cells (PBMC) to the apical channel, when the target is localized on the apical side of the epithelial cells. Measuring a parameter of the administration of the compound and the peripheral blood mononuclear cells.
-
公开(公告)号：US20180312546A1
公开(公告)日：2018-11-01
申请号：US15981316
申请日：2018-05-16
发明人： Haitao Guo , Dawei Cai , Andrea Cuconati , Changhua Ji
IPC分类号： C07K14/005 , G01N33/50
CPC分类号： C07K14/005 , C07K2319/40 , C07K2319/42 , C12N2730/10122 , C12N2730/10151 , C12N2830/006 , G01N33/502 , G01N2333/02
摘要： The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.
-
4.发明申请公开(公告)号：US20070044705A1
公开(公告)日：2007-03-01
申请号：US11511936
申请日：2006-08-28
申请人： Lei Du-Cuny , Manfred Kansy , Jörg Huwyler
发明人： Lei Du-Cuny , Manfred Kansy , Jörg Huwyler
IPC分类号： H01L21/322
CPC分类号： B01D9/0054
摘要： A method for crystallization of a weakly acidic and/or weakly basic compound having an uncharged form and at least one charged form comprises the steps of: a) providing a solution of said compound in a solvent having an initial pH-value and an initial total concentration of said compound, said initial pH-value being chosen such that the compound is present in said solution predominantly in said charged form, said initial total concentration being chosen larger than the intrinsic solubility of said uncharged form; b) gradually changing the pH-value of said solution in a direction that leads to a decrease of said compound's solubility until reaching a predetermined target pH-value at which said solution is in a substantially saturated state and the concentration of said uncharged form is substantially equal to said intrinsic solubility thereof; and c) maintaining said solution in a substantially saturated state while allowing formation of crystals of said compound.
摘要翻译： 用于结晶具有不带电荷形式和至少一种带电形式的弱酸性和/或弱碱性化合物的方法包括以下步骤：a）将所述化合物的溶液提供在具有初始pH值和初始总量的溶剂中 所述化合物的浓度，所述初始pH值被选择为使得化合物主要以所述带电形式存在于所述溶液中，所述初始总浓度选择为大于所述不带电形式的固有溶解度; b）在导致所述化合物溶解度降低的方向上逐渐改变所述溶液的pH值，直到达到所述溶液处于基本饱和状态的预定目标pH值，并且所述不带电形式的浓度基本上 等于其内在溶解度; 和c）将所述溶液保持在基本饱和状态，同时允许所述化合物的晶体形成。
-
5.发明申请Method for estimating the number of nuclei of a preselected isotope in a molecular species from and NMR spectrum 有权用于估计分子物质中的预选同位素核和核磁共振光谱的核数的方法公开(公告)号：US20050114043A1
公开(公告)日：2005-05-26
申请号：US10983077
申请日：2004-11-05
申请人： Alfred Ross
发明人： Alfred Ross
CPC分类号： G01R33/4625 , G01N24/08
摘要： A method for estimating the number of nuclei of a preselected isotope in a molecular species starts with an NMR spectrum of a sample containing said molecular species as a predominant substance, said NMR spectrum comprising a plurality of signal peaks corresponding to said nuclei. By applying inclusion and ordering criteria one obtains a set of ordered signal peaks, the integration of which leads to a set of ordered integrals. Nested outer and inner iteration cycles are carried out, wherein for each cycle a trial number of nuclei is assigned to one of said ordered integrals whilst the other ordered integrals are rescaled accordingly and rounded to the next integer value, so as to yield a candidate total number of nuclei. An estimated total number of nuclei is obtained by taking the lowest one from the plurality of candidate total numbers of nuclei that have the highest number of occurrences.
摘要翻译： 用于估计分子物种中预选同位素的核数的方法从包含所述分子物质作为主要物质的样品的NMR光谱开始，所述NMR光谱包括对应于所述核的多个信号峰。 通过应用包含和排序标准，可以获得一组有序信号峰值，其集成导致一组有序积分。 执行嵌套的外部和内部迭代循环，其中对于每个周期，将试验数量的核分配给所述有序积分之一，同时将其他有序积分相应地重新缩放，并舍入到下一个整数值，以产生候选总数 核数 通过从具有最高发生次数的多个核的候选总数中获取最低的核来获得估计的核数总数。
-
公开(公告)号：US20240352136A1
公开(公告)日：2024-10-24
申请号：US18687561
申请日：2022-09-02
发明人： Maria Amann , Laurène Pousse , Christophe Boetsch , Martin Weisser , Theresa Kolben , Vaios Karanikas , Jan Eckmann , Bruno Carneiro de Medeiros
IPC分类号： C07K16/28 , A61K31/496 , A61K31/706 , A61K39/395
CPC分类号： C07K16/2866 , A61K31/496 , A61K31/706 , A61K39/3955 , C07K2317/35 , C07K2317/40 , C07K2317/732
摘要： The present invention relates to anti-CD-25 antibodies for use in the treatment of acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).
-
7.发明公开公开(公告)号：US20240339191A1
公开(公告)日：2024-10-10
申请号：US18744107
申请日：2024-06-14
CPC分类号： G16H20/17 , A61B3/0025 , A61B3/102 , A61B3/1225 , G16H50/30
摘要： A method and system for predicting a selected treatment regimen for a subject. Baseline data for a subject diagnosed with neovascular age-related macular degeneration (nAMD) is received. A plurality of predictor inputs is formed for an outcome predictor using the baseline data and regimen data for a plurality of treatment regimens. The plurality of predictor inputs comprises a different predictor input for each of the plurality of treatment regimens. A plurality of treatment scores is generated for the plurality of treatment regimens via the set of outcome predictor using the plurality of predictor inputs. One of the plurality of treatment regimens is selected as a selected treatment regimen for the subject based on the plurality of treatment scores.
-
公开(公告)号：US20240338826A1
公开(公告)日：2024-10-10
申请号：US18578723
申请日：2022-07-14
CPC分类号： G06T7/0014 , G06V10/267 , G06V10/82 , G06T2207/20081 , G06T2207/20084 , G06T2207/30024 , G06T2207/30092
摘要： Systems and methods disclosed herein relate generally to systems and methods for detection, segmentation and characterization of isolated or overlapping object instances in digital images, applicable for detection, segmentation and characterization of crypts in histological images from patients with gastrointestinal disorders.
-
9.发明公开公开(公告)号：US20240338823A1
公开(公告)日：2024-10-10
申请号：US18744197
申请日：2024-06-14
IPC分类号： G06T7/00
CPC分类号： G06T7/0012 , G06T2207/20081 , G06T2207/30041
摘要： A method and system for detecting a presence of comorbid ocular conditions. Input data that includes imaging data for an eye of a subject is received. A score that indicates whether a presence of a plurality of comorbid ocular conditions is detected is generated in the eye of the subject using a deep learning model and the input data. A comorbidity output is generated based on the score. The comorbidity score may be a classification indicating whether the presence of the plurality of comorbid ocular conditions is detected.
-
公开(公告)号：US20240331877A1
公开(公告)日：2024-10-03
申请号：US18743437
申请日：2024-06-14
CPC分类号： G16H50/30 , G06T7/0012 , G06T7/10 , G16H10/20 , G16H10/60 , G16H20/10 , G16H50/20 , G06T2207/10101 , G06T2207/30041
摘要： A method and system for predicting fibrosis development. Optical coherence tomography (OCT) image data may be received for a retina of a subject with neovascular age-related macular degeneration (nAMD). The OCT image data is processed using a model system comprising a machine learning model to generate a prediction output. A final output is generated based on the prediction output in which the final output indicates a risk of developing fibrosis in the retina.
-
-
-
-
-
-
-
-
-
搜索结果
8129 条记录 (耗时 0.046 秒)
